{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:25:40Z","timestamp":1787117140204,"version":"build-2736575974"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant chemoimmunotherapy (NACI) improves outcomes in resectable lung squamous cell carcinoma (LUSC), yet response varies widely and current biomarkers lack precision. Novel correlates of immunotherapy sensitivity tailored to the LUSC tumor microenvironment (TME) are urgently needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using TCGA-LUSC transcriptomic data, we constructed a 25-gene prognostic model and applied three machine learning algorithms in combination with the Tumor Immune Dysfunction and Exclusion (TIDE) algorithm to identify core genes linked to prognosis and immunotherapy response. Immune infiltration and enrichment analyses were performed to characterize the TME. An independent pre-NACI biopsy cohort (n=36) was used for histopathological validation to explore correlations with pathological response, while single-cell RNA-seq (GSE207422) and CellChat were used to infer tumor-stromal crosstalk and explore underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The risk score independently stratified prognosis. Among three core genes, high MBNL2 expression was associated with higher TIDE scores, lower TIDE-predicted response rates, and elevated cancer-associated fibroblast (CAF) scores. scRNA-seq revealed systematically enhanced communication between MBNL2-high tumor cells and FAP\n                      <jats:sup>+<\/jats:sup>\n                      CAFs, with unique ligand-receptor pairs enriched in WNT and EGF pathways; FAP\n                      <jats:sup>+<\/jats:sup>\n                      CAFs interacted with regulatory T cells via ECM remodeling and the MDK-NCL axis. Histopathological validation confirmed that low tumor-cell MBNL2 expression correlated with higher pathological response and pCR rates, reduced FAP, and decreased FOXP3 expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study establishes a 25-gene prognostic model for LUSC and identifies MBNL2 as a novel correlate of poor pathological response to NACI. Elevated MBNL2 expression in tumor cells is associated with enhanced tumor-CAF crosstalk, CAF activation, and an immunosuppressive TME, laying a foundation for future mechanistic investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1877829","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:40:40Z","timestamp":1787114440000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omics identification of MBNL2 associated with poor pathological response to neoadjuvant chemoimmunotherapy in lung squamous cell carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Hao","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pathology, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]},{"name":"School of Basic Medical Sciences, Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, General Hospital of the Central Theatre Command","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haochen","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Pathology, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Wuhan University","place":["Wuhan, Hubei, China"]},{"name":"Department of Pathology, Zhongnan Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingping","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Renmin Hospital of Wuhan University","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00444-8","article-title":"Global variations in lung cancer incidence by histological subtype in 2020: a population-based study","volume":"24","author":"Zhang","year":"2023","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.09.018","article-title":"Squamous cell lung cancer: Current landscape and future therapeutic options","volume":"40","author":"Lau","year":"2022","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32517-x","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33142","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials","volume":"126","author":"Borghaei","year":"2020","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12885-023-10959-3","article-title":"Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003087","article-title":"Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better","volume":"10","author":"Zheng","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03370-8","article-title":"Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1\/PD-L1","volume":"26","author":"Shao","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41591-022-02163-w","article-title":"Persistent mutation burden drives sustained anti-tumor immune responses","volume":"29","author":"Niknafs","year":"2023","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41598-023-37000-8","article-title":"A novel prognostic model for hepatocellular carcinoma based on pyruvate metabolism-related genes","volume":"13","author":"Shi","year":"2023","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cam4.70284","article-title":"Predictive prognostic model for hepatocellular carcinoma based on seven genes participating in arachidonic acid metabolism","volume":"13","author":"Gu","year":"2024","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2174\/0115665232323373240905104033","article-title":"Characteristics of oxidative phosphorylation-related subtypes and construction of a prognostic signature in ovarian cancer","volume":"25","author":"Lu","year":"2025","journal-title":"Curr Gene Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2174\/0113892029382696251125102036","article-title":"Unveiling the role of sialylation-related lncRNAs in lung adenocarcinoma: a new prognostic model","volume":"26","author":"Yang","year":"2025","journal-title":"Curr Genomics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.799455","article-title":"Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade","volume":"12","author":"Genova","year":"2021","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320318110","article-title":"Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer","volume":"110","author":"Feig","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0098","article-title":"FAP delineates heterogeneous and functionally divergent stromal cells in immune-excluded breast tumors","volume":"6","author":"Cremasco","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41467-018-03348-z","article-title":"miR200-regulated CXCL12beta promotes fibroblast heterogeneity and immunosuppression in ovarian cancers","volume":"9","author":"Givel","year":"2018","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov"},{"key":"B28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for naive T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.08.010","article-title":"Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity","volume":"10","author":"Fu","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"B31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.immuni.2025.06.001","article-title":"The costimulatory molecule ICOS limits memory-like properties and function of exhausted PD-1(+)CD8(+) T cells","volume":"58","author":"Humblin","year":"2025","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01529-7","article-title":"The GPCR-G\u03b1s-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure","volume":"24","author":"Wu","year":"2023","journal-title":"Nat Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-23-1448","article-title":"Spatial and single-cell transcriptomics reveal a cancer-associated fibroblast subset in HNSCC that restricts infiltration and antitumor activity of CD8+ T cells","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202507695","article-title":"CYP4X1\/sEH-dependent endocannabinoid metabolism drives fibroblast-mediated immunosuppression to limit immunotherapy in colon cancer","volume":"13","author":"Mo","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2006-21.2022","article-title":"Calpain-2 mediates MBNL2 degradation and a developmental RNA processing program in neurodegeneration","volume":"42","author":"Wang","year":"2022","journal-title":"J Neurosci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac1219","article-title":"Alternative splicing mediates the compensatory upregulation of MBNL2 upon MBNL1 loss-of-function","volume":"51","author":"Nitschke","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad148","article-title":"Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1","volume":"146","author":"Nutter","year":"2023","journal-title":"Brain"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186416","article-title":"MBNL overexpression rescues cardiac phenotypes in a myotonic dystrophy type 1 heart mouse model","volume":"135","author":"Hu","year":"2025","journal-title":"J Clin Invest"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2026.107305","article-title":"MBNL2 dysfunction in outer radial glial cells is associated with disrupted corticogenesis in congenital myotonic dystrophy","volume":"221","author":"De Serres-Berard","year":"2026","journal-title":"Neurobiol Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.omtn.2021.04.005","article-title":"Alternative splicing perturbation landscape identifies RNA binding proteins as potential therapeutic targets in cancer","volume":"24","author":"Li","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.945668","article-title":"Elevated levels of the methyltransferase SETD2 causes transcription and alternative splicing changes resulting in oncogenic phenotypes","volume":"10","author":"Bhattacharya","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11577","article-title":"Paradoxical overexpression of MBNL2 in hepatocellular carcinoma inhibits tumor growth and invasion","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.7150\/jca.62816","article-title":"RNA-binding protein MBNL2 regulates cancer cell metastasis through MiR-182-MBNL2-AKT pathway","volume":"12","author":"Lin","year":"2021","journal-title":"J Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-24-1933","article-title":"Expression profile, regulatory mechanism and prognostic potential of MBNL2 in esophageal squamous cell carcinoma","volume":"14","author":"Zhang","year":"2025","journal-title":"Transl Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2024-0167","article-title":"MBNL2 enhances cisplatin resistance by regulating apoptosis in ovarian cancer cells","volume":"58","author":"Sung","year":"2025","journal-title":"BMB Rep"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-20-0263","article-title":"A Wnt-induced phenotypic switch in cancer-associated fibroblasts inhibits EMT in colorectal cancer","volume":"80","author":"Mosa","year":"2020","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbrc.2021.06.062","article-title":"Wnt5a in cancer-associated fibroblasts promotes colorectal cancer progression","volume":"568","author":"Hirashima","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1126\/sciadv.add7399","article-title":"Amphiregulin couples IL1RL1+ regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity","volume":"9","author":"Sun","year":"2023","journal-title":"Sci Adv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13402-025-01147-5","article-title":"Multi-omics profiling reveals that Scissor+ epithelial cells regulate intrahepatic metastasis of HCC via remodeling the metastatic microenvironment","volume":"49","author":"Zhu","year":"2026","journal-title":"Cell Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3389\/fimmu.2025.1563630","article-title":"Programmed cell death-related prognostic genes mediate dysregulation of the immune microenvironment in triple-negative breast cancer","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1877829\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T04:40:42Z","timestamp":1787114442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1877829\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":55,"alternative-id":["10.3389\/fonc.2026.1877829"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1877829","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1877829"}}